2021 American Transplant Congress
Evaluation of Conversion to Extended-Release Tacrolimus in Abdominal Organ and Thoracic Transplant Recipients
*Purpose: An established approach for conversion from immediate-release tacrolimus (IR TAC) to extended-release tacrolimus (LCPT) in kidney transplantation exists, but is lacking in other organ…2021 American Transplant Congress
Avoiding Tacrolimus Under- and Overexposure with a Dosing Algorithm for Renal Transplant Recipients: A Single Arm Prospective Intervention Trial
*Purpose: Bodyweight-based tacrolimus dosing followed by therapeutic drug monitoring is standard clinical care after renal transplantation. However, after transplantation, a meagre 38% of patients is…2021 American Transplant Congress
Modeling of Alternative Weight-Based Dosing Strategies of LCP-Tacrolimus in De Novo Kidney Transplant Patients
*Purpose: LCP-tacrolimus (LCPT; Envarsus XR®) is a modified-release once-daily formulation approved for prophylaxis of organ rejection in de novo kidney transplant patients in combination with…2021 American Transplant Congress
Anterior Rectus Sheath versus Standard Gibson Approach to Kidney Transplantation: A Randomized Double-blinded Controlled Trial
Glickman Urological and Kidney Institute, Cleveland Clinic, Cleveland, OH
*Purpose: Purpose: The anterior rectus sheath (ARS) approach to kidney transplantation (KT) involves a small skin incision to incise the ARS and medially retract rectus…2021 American Transplant Congress
Tacrolimus Dose Requirements in Lung Transplant Recipients on Systemic Azole Antifungals: The Influence of Race and Transplant Indication
*Purpose: CYP3A5 polymorphisms, drug interactions, and alterations in gastric absorption impact tacrolimus metabolism. This is important for those at higher risk of expressing these factors,…2021 American Transplant Congress
Impact of the Transplant Clinical Pharmacist in an Outpatient Transplant Clinic
1Emory University Hospital, Atlanta, GA, 2Emory Transplant Center, Atlanta, GA
*Purpose: Pharmacist involvement in the outpatient transplant clinic setting has been correlated with improved patient outcomes in single organ cohort studies. Direct clinical pharmacist involvement…2020 American Transplant Congress
A Novel Formula to Determine Optimal Immunosuppression in Renal Transplant Recipients Treated with Tacrolimus and Mycophenolate Mofetil: Towards Individualized Immunosuppression
*Purpose: Tacrolimus (TAC) and mycophenolic acid (MPA) remain the most commonly used drug combination for kidney transplant immunosuppression. Adequate drug dosing is challenging due to…2020 American Transplant Congress
Late Intra-Patient Tacrolimus Variability Predicts De Novo Donor-Specific Antibody and Graft Loss
*Purpose: Intra-patient variability (IPV) of tacrolimus level has been associated with poor outcomes after kidney transplantation. However, these findings were limited mainly to measurements early…2020 American Transplant Congress
Dosing and Outcomes of Conversion to Extended-Release Tacrolimus in Heart and Lung Transplant Recipients
*Purpose: Extended release tacrolimus (LCP-Tac) is a novel once daily formulation with improved pharmacokinetic parameters compared to immediate release tacrolimus (IR-Tac). LCP-Tac use in renal…2020 American Transplant Congress
De Novo Dosing of LCP-Tacrolimus Using Conservative Weight-Based Strategy Resulted in Supratherapeutic Trough Levels in Majority of Patients
University of Virginia Health System, Charlottesville, VA
*Purpose: Due to ongoing national drug shortages, our center transitioned to de novo use of LCP-tacrolimus (LCPT) in kidney transplant patients using a conservative dosing…
- « Previous Page
- 1
- 2
- 3
- 4
- 5
- …
- 9
- Next Page »